UAE: When women consciously chose to stay-at-home
Nandini Sircar/Dubai
Supplied photo
Reena returned to India in 2007 and rejoined Ranbaxy, while her family grew.
Transitioning from a researcher to a homemaker was not easy for Reena Khan, who holds a doctorate in biochemistry. Leaving her illustrious career at a top Indian pharmaceutical company was a hard enough choice, she said.
“Initially, I spent two years at Ranbaxy Gurgaon. I then got an opportunity to present a research paper on atherosclerosis at Keystone Symposium in Colorado, USA, in 2005. They liked my work and I was then offered a post-doctoral fellowship at Wake Forest Medical Centre, Winston-Salem. I loved my life and work in the US. I even managed to get published in good research journals. Everything was perfect,” she said.
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” conference this afternoon at 12:15 p.m. MST. The presentation will provide an update on progress with the Kaleido MMT
TM platform, including a review of the K031 COVID-19 study interim data that were announced on January 14, 2021.
“We are pleased to have this opportunity to present our chemistry-driven approach to leverage the therapeutic potential of the microbiome and additional details of our interim analysis, including statistical analysis of the effects of KB109 on symptom resolution in patients with mild-to-moderate COVID-19,” commented Johan van Hylckama Vlieg, Ph.D.,
Second Genome To Present Biomarker Data in Oncology at Keystone Symposium Company Identifies Microbiome-based Composite Biomarker Predictive of Response to Immune Checkpoint Inhibitor
News provided by
Share this article
Share this article
SAN FRANCISCO, Jan. 19, 2021 /PRNewswire/ Second Genome, a leader in microbiome science, will present data today demonstrating the identification of a microbiome-based composite biomarker which can be used to predict response to immune checkpoint inhibitors. The data will be presented at the Keystone Symposium entitled Harnessing the Microbiome for Disease Prevention and Therapy being held from January 18-20. The oral presentation will be included in The Microbiome and Cancer session and is titled Microbiome-based biomarker predicts response to immune checkpoint inhibitor therapy in a melanoma meta-cohort independently of clinical features.
DGAP-News: Formycon AG: Formycons wissenschaftliche Kooperationspartner präsentieren FYB207-Ergebnisse auf internationalem Keystone Symposium finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.